Childhood Cancer Predisposition Study (CCPS)
Launched by EMORY UNIVERSITY · Aug 11, 2020
Trial Information
Current as of May 08, 2025
Recruiting
Keywords
ClinConnect Summary
The Childhood Cancer Predisposition Study (CCPS) is a research project focused on understanding why some children are more likely to develop cancer due to genetic factors. This study aims to gather information and samples from children who have certain genetic conditions that increase their risk for cancer, as well as their family members. By studying these high-risk individuals, researchers hope to learn more about how cancer develops, improve early detection methods, and find ways to prevent cancer in children.
To participate in the study, children must be under 21 years old and have a diagnosis of a specific genetic condition related to cancer, even if they have not had cancer themselves. Family members, including parents and siblings, may also join the study based on their own health history. Participants can expect to provide some clinical information and biological samples, which will help advance our understanding of childhood cancers and ultimately improve care and outcomes for young patients. If you have any questions about eligibility or what being part of the study involves, the research team is available to help.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Primary Subjects must meet all of the below criteria to be eligible for enrollment:
- • 1. Be less than 21 years of age at the time of enrollment
- • 2. Have a diagnosis of a specific CPS, whether they have had cancer or not
- • Based on clinical laboratory testing demonstrating a Pathogenic or Likely Pathogenic germline variant and/or
- • Based on well-established clinical diagnostic criteria and/or
- • Based on high clinical suspicion of a specific CPS with clinical laboratory testing demonstrating a variant of uncertain significance (VUS)
- Affected Parents must meet all of the following criteria to be eligible for enrollment:
- • 1. Be the biologic parent of a Primary Subject and
- • 2. Carry a diagnosis (or obligate diagnosis) of the familial CPS
- Adult Affected Siblings must meet all of the following criteria to be eligible for enrollment:
- • 1. Be the biologic sibling of a Primary Subject and
- • 2. Carry a diagnosis (or obligate diagnosis) of the familial CPS
- • Unaffected Parents and Siblings must meet all of the following criteria to be eligible for enrollment
- • 1. Be the biologic parent or sibling of a Primary Subject and
- • 2. Not carry a diagnosis (or obligate diagnosis) of the familial CPS
- Affected Family Members must meet all of the following criteria to be eligible for enrollment:
- • 1. Carry a diagnosis of (or obligate diagnosis of) the familial CPS. Documentation is requested but not required.
- • More than one child from a Primary Family Unit may be a Primary Subject. An Unaffected Sibling may be reclassified as a Primary Subject if diagnosed with a CPS during childhood.
- Exclusion Criteria:
- • Individuals with a strong personal or family history of cancer without a genetic or clinical diagnosis of a specific CPS are not eligible for enrollment.
About Emory University
Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Philadelphia, Pennsylvania, United States
Boston, Massachusetts, United States
Salt Lake City, Utah, United States
Toronto, Ontario, Canada
Memphis, Tennessee, United States
Atlanta, Georgia, United States
Patients applied
Trial Officials
Christopher Porter, MD
Principal Investigator
Emory University
Anita Villani, MD
Principal Investigator
The Hospital for Sick Children
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials